133 related articles for article (PubMed ID: 35342104)
21. KRAS exon 2 codon 13 mutation is associated with a better prognosis than codon 12 mutation following lung metastasectomy in colorectal cancer.
Renaud S; Guerrera F; Seitlinger J; Costardi L; Schaeffer M; Romain B; Mossetti C; Claire-Voegeli A; Filosso PL; Legrain M; Ruffini E; Falcoz PE; Oliaro A; Massard G
Oncotarget; 2017 Jan; 8(2):2514-2524. PubMed ID: 27911859
[TBL] [Abstract][Full Text] [Related]
22. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
Stintzing S; Miller-Phillips L; Modest DP; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V;
Eur J Cancer; 2017 Jul; 79():50-60. PubMed ID: 28463756
[TBL] [Abstract][Full Text] [Related]
23. Coaltered
Datta J; Smith JJ; Chatila WK; McAuliffe JC; Kandoth C; Vakiani E; Frankel TL; Ganesh K; Wasserman I; Lipsyc-Sharf M; Guillem J; Nash GM; Paty PB; Weiser MR; Saltz LB; Berger MF; Jarnagin WR; Balachandran V; Kingham TP; Kemeny NE; Cercek A; Garcia-Aguilar J; Taylor BS; Viale A; Yaeger R; Solit DB; Schultz N; D'Angelica MI
Clin Cancer Res; 2020 Mar; 26(5):1077-1085. PubMed ID: 31719050
[TBL] [Abstract][Full Text] [Related]
24. Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
Lee DW; Han SW; Cha Y; Bae JM; Kim HP; Lyu J; Han H; Kim H; Jang H; Bang D; Huh I; Park T; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY
Cancer; 2017 Sep; 123(18):3513-3523. PubMed ID: 28513830
[TBL] [Abstract][Full Text] [Related]
25. Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection.
Passot G; Denbo JW; Yamashita S; Kopetz SE; Chun YS; Maru D; Overman MJ; Brudvik KW; Conrad C; Aloia TA; Vauthey JN
Surgery; 2017 Feb; 161(2):332-340. PubMed ID: 27592215
[TBL] [Abstract][Full Text] [Related]
26. A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial.
Hagman H; Frödin JE; Berglund Å; Sundberg J; Vestermark LW; Albertsson M; Fernebro E; Johnsson A
Ann Oncol; 2016 Jan; 27(1):140-7. PubMed ID: 26483047
[TBL] [Abstract][Full Text] [Related]
27. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM
JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887
[TBL] [Abstract][Full Text] [Related]
28. KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer.
Renaud S; Romain B; Falcoz PE; Olland A; Santelmo N; Brigand C; Rohr S; Guenot D; Massard G
Br J Cancer; 2015 Feb; 112(4):720-8. PubMed ID: 25688918
[TBL] [Abstract][Full Text] [Related]
29. Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis.
Tosi F; Magni E; Amatu A; Mauri G; Bencardino K; Truini M; Veronese S; De Carlis L; Ferrari G; Nichelatti M; Sartore-Bianchi A; Siena S
Clin Colorectal Cancer; 2017 Sep; 16(3):e153-e163. PubMed ID: 28216246
[TBL] [Abstract][Full Text] [Related]
30. Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan.
Ikoma T; Shimokawa M; Kotaka M; Matsumoto T; Nagai H; Boku S; Shibata N; Yasui H; Satake H
BMC Cancer; 2021 May; 21(1):518. PubMed ID: 33962575
[TBL] [Abstract][Full Text] [Related]
31. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
Vauthey JN; Zimmitti G; Kopetz SE; Shindoh J; Chen SS; Andreou A; Curley SA; Aloia TA; Maru DM
Ann Surg; 2013 Oct; 258(4):619-26; discussion 626-7. PubMed ID: 24018645
[TBL] [Abstract][Full Text] [Related]
32. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.
Kubicka S; Greil R; André T; Bennouna J; Sastre J; Van Cutsem E; von Moos R; Osterlund P; Reyes-Rivera I; Müller T; Makrutzki M; Arnold D;
Ann Oncol; 2013 Sep; 24(9):2342-9. PubMed ID: 23852309
[TBL] [Abstract][Full Text] [Related]
33. Anatomical Resections Improve Survival Following Lung Metastasectomy of Colorectal Cancer Harboring KRAS Mutations.
Renaud S; Seitlinger J; Lawati YA; Guerrera F; Falcoz PE; Massard G; Ferri L; Spicer J
Ann Surg; 2019 Dec; 270(6):1170-1177. PubMed ID: 29781848
[TBL] [Abstract][Full Text] [Related]
34. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.
Ince WL; Jubb AM; Holden SN; Holmgren EB; Tobin P; Sridhar M; Hurwitz HI; Kabbinavar F; Novotny WF; Hillan KJ; Koeppen H
J Natl Cancer Inst; 2005 Jul; 97(13):981-9. PubMed ID: 15998951
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
Sastre J; Vidaurreta M; Gómez A; Rivera F; Massutí B; López MR; Abad A; Gallen M; Benavides M; Aranda E; Rubio ED;
Clin Colorectal Cancer; 2013 Dec; 12(4):280-6. PubMed ID: 24012456
[TBL] [Abstract][Full Text] [Related]
36. Are high initial CEA and CA 19-9 levels associated with the presence of K-ras mutation in patients with metastatic colorectal cancer?
Selcukbiricik F; Bilici A; Tural D; Erdamar S; Soyluk O; Buyukunal E; Demirelli F; Serdengecti S
Tumour Biol; 2013 Aug; 34(4):2233-9. PubMed ID: 23625655
[TBL] [Abstract][Full Text] [Related]
37. Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results.
Mohamed A; Twardy B; AbdAllah N; Akhras A; Ismail H; Zordok M; Schrapp K; Attumi T; Tesfaye A; El-Rayes B
J Gastrointest Cancer; 2019 Jun; 50(2):269-275. PubMed ID: 29388061
[TBL] [Abstract][Full Text] [Related]
38. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
[TBL] [Abstract][Full Text] [Related]
39. Use of a High-Throughput Genotyping Platform (OncoMap) for
Kim D; Hong YS; Kim JE; Kim KP; Lee JL; Chun SM; Kim J; Jang SJ; Kim TW
Cancer Res Treat; 2017 Jan; 49(1):37-43. PubMed ID: 27121720
[TBL] [Abstract][Full Text] [Related]
40. RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy.
Osumi H; Shinozaki E; Suenaga M; Matsusaka S; Konishi T; Akiyoshi T; Fujimoto Y; Nagayama S; Fukunaga Y; Ueno M; Mise Y; Ishizawa T; Inoue Y; Takahashi Y; Saiura A; Uehara H; Mun M; Okumura S; Mizunuma N; Miki Y; Yamaguchi T
Int J Cancer; 2016 Aug; 139(4):803-11. PubMed ID: 27004837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
